Market Place
Sourcing Support
Palisade Bio Presents PALI-2108 Preclinical Results for Crohn’s & UC
21 Nov 2024 //
GLOBENEWSWIRE
Palisade Bio CMO Mitch Jones to Present at AFDD Summit
14 Nov 2024 //
GLOBENEWSWIRE
Palisade Bio Doses First Subject in PALI-2108 UC Phase 1 Study
07 Nov 2024 //
GLOBENEWSWIRE
Palisade Bio Reports Positive Ulcerative Colitis Data for PALI-2108
31 Oct 2024 //
GLOBENEWSWIRE
Palisade Bio Abstract Accepted At ACG 2024 Annual Scientific Meeting
15 Oct 2024 //
GLOBENEWSWIRE
Palisade Bio Cleared For PALI-2108 Phase 1 In Ulcerative Colitis
10 Oct 2024 //
GLOBENEWSWIRE
Palisade Bio To Participate In 2024 Maxim Healthcare Summit
08 Oct 2024 //
GLOBENEWSWIRE
Palisade Bio Updates On PALI-2108 Phase 1 Study Launch
25 Sep 2024 //
GLOBENEWSWIRE
Palisade Bio Launches New Branding And Reiterates Commitment
16 Sep 2024 //
GLOBENEWSWIRE
Palisade Bio bolsters branding with bold new logo, website makeover
16 Sep 2024 //
FIERCE PHARMA
Palisade Bio Reports Data On PDE4B Expression In Patients Cohorts
05 Sep 2024 //
GLOBENEWSWIRE
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 Aug 2024 //
GLOBENEWSWIRE
Palisade Bio Reports Q2 2024 Results And Provides Business Update
13 Aug 2024 //
GLOBENEWSWIRE
Palisade Bio Selects Dose For Phase 1 Study Of PALI-2108
08 Aug 2024 //
GLOBENEWSWIRE
Palisade Bio Participates in Virtual Investor “What this Means” Segment
31 Jul 2024 //
GLOBENEWSWIRE
Palisade Bio Completes Microbiome Study For PALI-2108 Bioactivation
29 Jul 2024 //
GLOBENEWSWIRE
Palisade Bio`s PALI-2108 Patent To Be Granted By European Patent Office
19 Jul 2024 //
GLOBENEWSWIRE
Palisade Bio Completes First GMP Manufacturing Of PALI-2108
11 Jul 2024 //
GLOBENEWSWIRE
Palisade Bio to Participate in the Virtual Investor Closing Bell Series
24 Jun 2024 //
GLOBENEWSWIRE
Palisade Bio Updates Strategic Collaboration with Strand Life Sciences
21 Jun 2024 //
GLOBENEWSWIRE
Palisade Bio Announces NOA for Canadian Patent Covering Lead Product , PALI-2108
11 Jun 2024 //
GLOBENEWSWIRE
Palisade Bio to Present at the Virtual Investor Pitch Conference
10 Jun 2024 //
GLOBENEWSWIRE
Palisade`s ulcerative colitis drug prevents symptoms in mice
23 May 2024 //
FIERCE BIOTECH
Palisade`s PALI-2108 Shows Bioactivation, Efficacy In Mouse Models
21 May 2024 //
GLOBENEWSWIRE
Palisade Bio Reports Q1 2024 Results, Business Update
14 May 2024 //
GLOBENEWSWIRE
Palisade Bio Closes $4M Private Placement Under Nasdaq Rules
07 May 2024 //
GLOBENEWSWIRE
Palisade Bio Appoints Margery Fischbein to its Board of Directors
07 May 2024 //
GLOBENEWSWIRE
Palisade Bio $4M Private Placement At-The-Market Per Nasdaq
02 May 2024 //
GLOBENEWSWIRE
Palisade Bio, Strand Partner On Precision Medicine
23 Apr 2024 //
GLOBENEWSWIRE
Palisade Bio Demonstrates PALI-2108 Bioactivation in Ulcerative Colitis Study
16 Apr 2024 //
GLOBENEWSWIRE
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
11 Apr 2024 //
GLOBENEWSWIRE
Palisade Bio Presents Development Overview of PALI-2108
10 Apr 2024 //
GLOBENEWSWIRE
Palisade Bio Announces 1-for-15 Reverse Stock Split
03 Apr 2024 //
GLOBENEWSWIRE
Palisade Bio Reports Year End 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
15 Feb 2024 //
GLOBENEWSWIRE
Palisade Bio Provides Corporate Update and Reiterates Guidance
13 Feb 2024 //
GLOBENEWSWIRE
Palisade Bio Announces Formation of Clinical Advisory Board
08 Feb 2024 //
GLOBENEWSWIRE
Correction Notice of Palisade Bio™s Press Release
08 Feb 2024 //
GLOBENEWSWIRE
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
30 Jan 2024 //
GLOBENEWSWIRE
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108
29 Jan 2024 //
GLOBENEWSWIRE
Palisade Bio Selected for Poster Presentation at 2024 Crohn™s & Colitis Congress
09 Jan 2024 //
GLOBENEWSWIRE
Palisade Bio Announces Receipt of Second Milestone Payment for PALI-2108
28 Dec 2023 //
GLOBENEWSWIRE
Palisade Bio Reports Third Quarter 2023 Financial Results
10 Nov 2023 //
GLOBENEWSWIRE
Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference
11 Oct 2023 //
GLOBENEWSWIRE
Palisade Bio Appoints Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
11 Sep 2023 //
GLOBENEWSWIRE
Palisade Bio Announces Closing of $2 Million Registered Direct Offering
11 Sep 2023 //
GLOBENEWSWIRE
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock
07 Sep 2023 //
GLOBENEWSWIRE
Palisade Bio Transforms GI-Focused Pipeline Through Agreement with Giiant Pharma
06 Sep 2023 //
GLOBENEWSWIRE
Palisade Bio Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
GLOBENEWSWIRE
Palisade Bio Announces Results from U.S. Phase 2 PROFILE Study Evaluating LB1148
09 Aug 2023 //
GLOBENEWSWIRE
Palisade`s stock collapses as sole asset flunks phase 2 GI trial
09 Aug 2023 //
FIERCE BIOTECH
Palisade Announces Completion of Enrollment in LB1148 Dose Optimization Study
05 Jul 2023 //
GLOBENEWSWIRE
Palisade Bio Participate in the Healthcare Virtual Conference
14 Jun 2023 //
GLOBENEWSWIRE
Palisade Bio Promotes J.D. Finley to Chief Executive Officer
01 Jun 2023 //
GLOBENEWSWIRE
Palisade Bio LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
24 May 2023 //
GLOBENEWSWIRE
Palisade Bio Reports First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
Palisade Bio initiates enrolment, dosing in serine protease inhibitor study
12 May 2023 //
CLINICAL TRIALS ARENA
Palisade Bio Announces Dosing of First Patient in LB1148 Dose Optimization Study
11 May 2023 //
GLOBENEWSWIRE
Palisade Bio Receives Canadian Patent Covering Composition of LB1148
06 Apr 2023 //
GLOBENEWSWIRE
Palisade Announces Enrollment of First Patient in PIII Trial Evaluating LB1148
05 Apr 2023 //
GLOBENEWSWIRE
